Los Angeles Capital Management LLC Has $93,000 Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Los Angeles Capital Management LLC trimmed its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 74.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,077 shares of the biotechnology company’s stock after selling 65,854 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Anavex Life Sciences were worth $93,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Rhumbline Advisers boosted its holdings in Anavex Life Sciences by 15.8% in the second quarter. Rhumbline Advisers now owns 119,289 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 16,293 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Anavex Life Sciences by 17.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock valued at $1,184,000 after acquiring an additional 40,895 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Anavex Life Sciences in the 2nd quarter valued at approximately $57,000. Fiduciary Alliance LLC lifted its holdings in Anavex Life Sciences by 45.2% in the 2nd quarter. Fiduciary Alliance LLC now owns 19,275 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Virtu Financial LLC boosted its position in Anavex Life Sciences by 87.5% during the first quarter. Virtu Financial LLC now owns 40,612 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 18,954 shares during the period. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Stock Up 7.3 %

AVXL opened at $5.70 on Tuesday. Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $10.45. The firm has a market capitalization of $483.36 million, a P/E ratio of -11.40 and a beta of 0.62. The stock’s 50 day moving average price is $5.97 and its two-hundred day moving average price is $4.88.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. During the same quarter in the prior year, the company earned ($0.14) earnings per share. As a group, analysts anticipate that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on AVXL shares. EF Hutton Acquisition Co. I raised shares of Anavex Life Sciences to a “strong-buy” rating in a research report on Monday, July 22nd. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Anavex Life Sciences in a research report on Thursday, August 1st.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.